MARKET

CLBS

CLBS

Caladrius
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.790
-0.030
-1.65%
After Hours: 1.820 +0.03 +1.68% 19:59 03/05 EST
OPEN
1.800
PREV CLOSE
1.820
HIGH
1.805
LOW
1.600
VOLUME
4.03M
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
1.050
MARKET CAP
104.60M
P/E (TTM)
-2.8233
1D
5D
1M
3M
1Y
5Y
Caladrius Biosciences Receives Orphan Designation Status For 'GCSF-mobilized autologous CD34+ cells' For Treatment Of Buerger's Disease
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=805020
Benzinga · 3d ago
Caladrius Biosciences, Inc. (CLBS) Upgraded to Buy: What Does It Mean for the Stock?
Zacks.com · 3d ago
Blueprint Medicines (BPMC) Gets EMA Validation for Ayvakyt in SM
Zacks.com · 3d ago
Stem Cells Market Expansion Projected to Gain an Uptick During 2021-2026
Mar 04, 2021 (AmericaNewsHour) -- According to Market Research, the Global Stem Cells Market was valued at USD 5.88 Billion in 2018 and is expected to...
AmericaNewsHour · 3d ago
DJ Caladrius Biosciences Price Target Raised to $10.00/Share From $7.00 by Brookline Capital
Dow Jones · 4d ago
DJ Caladrius Biosciences Is Maintained at Buy by Brookline Capital
Dow Jones · 4d ago
Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
BASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, an...
GlobeNewswire · 4d ago
--Analyst Actions: Brookline Capital Management Adjusts Caladrius Biosciences PT to $10 From $7, Maintains Buy Rating
MT Newswires · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLBS. Analyze the recent business situations of Caladrius through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLBS stock price target is 10.00 with a high estimate of 14.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 2.41M
% Owned: 4.12%
Shares Outstanding: 58.43M
TypeInstitutionsShares
Increased
10
223.24K
New
9
278.18K
Decreased
5
65.64K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Gregory Brown
President/Chief Executive Officer/Director
David Mazzo
Senior Vice President/General Counsel/Secretary
Todd Girolamo
Other
Robert Honigberg
Director
Michael Davidson
Director
Anne Whitaker
Independent Director
Steven Klosk
Independent Director
Steven Myers
Independent Director
Cynthia Schwalm
Independent Director
Peter Traber
No Data
  • All
  • Financials
  • Insiders
More
About CLBS
Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. It also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.

Webull offers kinds of Caladrius Biosciences Inc stock information, including NASDAQ:CLBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLBS stock methods without spending real money on the virtual paper trading platform.